Geode Capital Management, LLC Cytom X Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

  • $1.21 Trillion
  • Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 803,531 shares of CTMX stock, worth $883,884. This represents 0.0% of its overall portfolio holdings.

Number of Shares
803,531
Previous 769,499 4.42%
Holding current value
$883,884
Previous $938,000 1.07%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$1.12 - $1.51 $38,115 - $51,388
34,032 Added 4.42%
803,531 $948,000
Q2 2024

Aug 09, 2024
BUY
$1.21 - $5.13 $19,482 - $82,598
16,101 Added 2.14%
769,499 $938,000
Q1 2024

May 13, 2024
BUY
$1.41 - $2.74 $71,549 - $139,038
50,744 Added 7.22%
753,398 $1.64 Million
Q4 2023

Feb 13, 2024
BUY
$1.07 - $1.55 $28,152 - $40,782
26,311 Added 3.89%
702,654 $1.09 Million
Q3 2023

Nov 13, 2023
BUY
$1.26 - $1.87 $40,642 - $60,318
32,256 Added 5.01%
676,343 $872,000
Q2 2023

Aug 11, 2023
BUY
$1.41 - $1.92 $2,508 - $3,415
1,779 Added 0.28%
644,087 $1.11 Million
Q1 2023

May 15, 2023
BUY
$1.48 - $2.88 $58,064 - $112,991
39,233 Added 6.51%
642,308 $969,000
Q4 2022

Feb 13, 2023
BUY
$1.19 - $1.91 $18,592 - $29,841
15,624 Added 2.66%
603,075 $964,000
Q3 2022

Nov 14, 2022
BUY
$1.23 - $1.97 $5,394 - $8,640
4,386 Added 0.75%
587,451 $851,000
Q2 2022

Aug 12, 2022
SELL
$1.53 - $2.89 $714,636 - $1.35 Million
-467,083 Reduced 44.48%
583,065 $1.07 Million
Q1 2022

May 13, 2022
SELL
$2.67 - $4.68 $330,276 - $578,911
-123,699 Reduced 10.54%
1,050,148 $2.8 Million
Q4 2021

Feb 11, 2022
BUY
$3.87 - $7.39 $196,456 - $375,145
50,764 Added 4.52%
1,173,847 $5.08 Million
Q3 2021

Nov 12, 2021
SELL
$4.32 - $6.43 $129,284 - $192,430
-29,927 Reduced 2.6%
1,123,083 $5.72 Million
Q2 2021

Aug 13, 2021
BUY
$6.33 - $9.91 $477,231 - $747,134
75,392 Added 7.0%
1,153,010 $7.3 Million
Q1 2021

May 12, 2021
BUY
$6.6 - $9.0 $2.11 Million - $2.87 Million
319,304 Added 42.11%
1,077,618 $8.33 Million
Q4 2020

Feb 12, 2021
BUY
$6.47 - $7.9 $33,320 - $40,685
5,150 Added 0.68%
758,314 $4.97 Million
Q3 2020

Nov 13, 2020
BUY
$6.55 - $8.83 $290,001 - $390,948
44,275 Added 6.25%
753,164 $5.01 Million
Q2 2020

Aug 13, 2020
BUY
$7.4 - $14.64 $27,394 - $54,197
3,702 Added 0.52%
708,889 $5.91 Million
Q1 2020

May 14, 2020
BUY
$3.61 - $8.6 $176,637 - $420,798
48,930 Added 7.46%
705,187 $5.41 Million
Q4 2019

Feb 13, 2020
BUY
$5.17 - $8.91 $202,720 - $349,370
39,211 Added 6.35%
656,257 $5.45 Million
Q3 2019

Nov 12, 2019
BUY
$7.38 - $12.25 $133,245 - $221,173
18,055 Added 3.01%
617,046 $4.55 Million
Q2 2019

Aug 14, 2019
BUY
$9.35 - $11.41 $20,354 - $24,839
2,177 Added 0.36%
598,991 $6.72 Million
Q1 2019

May 14, 2019
BUY
$9.5 - $19.16 $284,173 - $573,133
29,913 Added 5.28%
596,814 $6.42 Million
Q4 2018

Feb 13, 2019
BUY
$12.69 - $18.61 $669,219 - $981,416
52,736 Added 10.26%
566,901 $8.56 Million
Q3 2018

Nov 13, 2018
BUY
$18.04 - $26.41 $2.72 Million - $3.99 Million
151,037 Added 41.59%
514,165 $9.51 Million
Q2 2018

Aug 14, 2018
BUY
$21.38 - $29.68 $702,418 - $975,106
32,854 Added 9.95%
363,128 $8.3 Million
Q1 2018

May 15, 2018
SELL
$21.76 - $34.22 $374,250 - $588,549
-17,199 Reduced 4.95%
330,274 $9.4 Million
Q4 2017

Feb 13, 2018
BUY
$19.0 - $23.09 $409,412 - $497,543
21,548 Added 6.61%
347,473 $7.33 Million
Q3 2017

Nov 14, 2017
BUY
$13.53 - $18.17 $1.23 Million - $1.66 Million
91,162 Added 38.83%
325,925 $5.92 Million
Q2 2017

Aug 14, 2017
BUY
N/A
234,763
234,763 $3.64 Million

Others Institutions Holding CTMX

# of Institutions
71
Shares Held
50.7M
Call Options Held
112K
Put Options Held
8.3K
View Full List

About CytomX Therapeutics, Inc.

CTMX Quotes by TradingView
  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $72.5M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email